ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

IMMP Immutep Ltd

2.98
0.11 (3.83%)
31 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Immutep Ltd IMMP NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.11 3.83% 2.98 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.93 2.87 3.05 2.98 2.87
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
15/5/202407:00GLOBEImmutep Presents Data from Safety Lead-in Phase of AIPAC-003..
02/5/202407:00GLOBEPositive Initial Clinical Data Reported from Immutep’s Efti..
29/4/202407:00GLOBEImmutep Quarterly Activities Report Q3 FY24
24/4/202407:00GLOBEImmutep Announces Positive Preliminary Topline Results from..
18/4/202407:00GLOBEImmutep Appoints Leading Research Institute to Conduct..
17/4/202407:00GLOBEImmutep Receives Positive Feedback from the Spanish..
05/3/202407:00GLOBEImmutep Announces First Clinical Data from 90mg Dosing of..
30/1/202415:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202407:00GLOBEImmutep Quarterly Activities Report Q2 FY24
04/1/202407:00GLOBEFirst Patient Dosed in Trial Evaluating Efti and the..
21/12/202307:00GLOBEImmutep Receives Constructive Regulatory Feedback on..
21/12/202305:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/12/202307:00GLOBEImmutep Receives A$2.6 million R&D Tax Incentive from French..
22/11/202307:00GLOBEImmutep Announces Site Expansion for INSIGHT-003 Phase I..
09/11/202307:00GLOBEImmutep Completes Enrollment in TACTI-003 Phase IIb Trial of..
06/11/202307:00GLOBEImmutep Announces Completion of the Safety Lead-In and..
03/11/202311:00GLOBEImmutep Announces New Biomarker Data from TACTI-002 Phase II..
03/11/202305:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202307:00GLOBEImmutep to Participate in November Investor Events
31/10/202307:00GLOBEImmutep Quarterly Activities Report Q1 FY24
25/10/202307:00GLOBEImmutep receives ~A$1.13 million R&D Tax Incentive
25/10/202305:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/10/202307:00GLOBEImmutep Reports Promising Clinical Data from INSIGHT-003..
24/10/202305:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/10/202307:00GLOBEImmutep’s Efti in Combination with KEYTRUDA® Generates..
16/10/202307:00GLOBEImmutep Announces Publication of Abstracts at ESMO Congress..
03/10/202307:00GLOBEImmutep Announces Abstract Accepted for Presentation at the..
21/9/202307:00GLOBECommercial Manufacturing of Eftilagimod Alpha at 2000L Scale..
05/9/202308:00GLOBEImmutep to Participate in September Investor Conferences
01/8/202307:00GLOBEImmutep Receives Positive Scientific Advice from European..
31/7/202307:00GLOBEImmutep to Present Overall Survival Data in 1st Line..
28/7/202307:00GLOBEFirst Patient Dosed in Chemotherapy-Free Triple Combination..
28/7/202305:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/6/202307:00GLOBEImmutep Secures Third United States Patent for Eftilagimod..
20/6/202307:00GLOBEImmutep Granted United States Patent for IMP761, a..
07/6/202307:00GLOBEImmutep to Participate at the Jefferies Healthcare..
05/6/202307:00GLOBEImmutep Reports Final Positive Data in 2nd Line Head and..
02/6/202307:00GLOBEImmutep Successfully Completes Institutional Placement and..

Su Consulta Reciente

Delayed Upgrade Clock